Sunitinib re-challenge in advanced renal-cell carcinoma

Despite offering significant clinical benefits in advanced renal-cell carcinoma (RCC), the effectiveness of targeted therapies eventually declines with the development of resistance. Defining optimal sequences of therapy is therefore the focus of much current research. There is also evidence that tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Porta, C, Paglino, C, Grünwald, V
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2014
Materias:
Minireview
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4453836/
https://www.ncbi.nlm.nih.gov/pubmed/24800947
http://dx.doi.org/10.1038/bjc.2014.214

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4453836/
https://www.ncbi.nlm.nih.gov/pubmed/24800947
http://dx.doi.org/10.1038/bjc.2014.214

Ejemplares similares